239 related articles for article (PubMed ID: 29082524)
1. Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study.
Boyar Cetinkaya R; Aagnes B; Myklebust TÅ; Thiis-Evensen E
Int J Cancer; 2018 Mar; 142(6):1139-1147. PubMed ID: 29082524
[TBL] [Abstract][Full Text] [Related]
2. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
3. Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria.
Martin JA; Warner RR; Wisnivesky JP; Kim MK
Eur J Cancer; 2017 May; 76():197-204. PubMed ID: 28334622
[TBL] [Abstract][Full Text] [Related]
4. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
Masui T; Ito T; Komoto I; Uemoto S;
BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
[TBL] [Abstract][Full Text] [Related]
5. Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients.
Nikou GC; Pazaitou-Panayiotou K; Dimitroulopoulos D; Alexandrakis G; Papakostas P; Vaslamatzis M; Kaldrymidis P; Markussis V; Koumarianou A;
BMC Endocr Disord; 2016 Feb; 16():8. PubMed ID: 26872616
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
7. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
9. Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010.
Boyar Cetinkaya R; Aagnes B; Thiis-Evensen E; Tretli S; Bergestuen DS; Hansen S
Neuroendocrinology; 2017; 104(1):1-10. PubMed ID: 26562558
[TBL] [Abstract][Full Text] [Related]
10. Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm.
Cavalcoli F; Pusceddu S; Zilli A; Tamagno G; Femia D; Prinzi N; Travers J; Consonni D; Ciafardini C; Conte D; Massironi S
Scand J Gastroenterol; 2019 Sep; 54(9):1111-1117. PubMed ID: 31454281
[No Abstract] [Full Text] [Related]
11. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
[TBL] [Abstract][Full Text] [Related]
12. The overriding role of surgery and tumor grade for long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based cohort study.
Søreide JA; Kvaløy JT; Lea D; Sandvik OM; Al-Saiddi M; Haslerud TM; Garresori H; Karlsen LN; Gudlaugsson E; Søreide K
Cancer Rep (Hoboken); 2022 Feb; 5(2):e1462. PubMed ID: 34105314
[TBL] [Abstract][Full Text] [Related]
13. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
14. Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms.
Yao H; Hu G; Jiang C; Fan M; Yuan L; Shi H; Lin R
Front Endocrinol (Lausanne); 2023; 14():1241724. PubMed ID: 37701903
[TBL] [Abstract][Full Text] [Related]
15. Prognoses in patients with primary gastrointestinal neuroendocrine neoplasms based on the proposed new classification scheme.
Yin XN; Shen CY; Yin YQ; Chen HJ; Chen HN; Yin Y; Han LY; Chen JJ; Tang SM; Chen ZX; Zhang B
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e37-e44. PubMed ID: 28856815
[TBL] [Abstract][Full Text] [Related]
16. Digestive Neuroendocrine Tumor Distribution and Characteristics According to the 2010 WHO Classification: a Single Institution Experience in Lebanon.
Kourie HR; Ghorra C; Rassy M; Kesserouani C; Kattan J
Asian Pac J Cancer Prev; 2016; 17(5):2679-81. PubMed ID: 27268650
[TBL] [Abstract][Full Text] [Related]
17. Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland.
Alwan H; La Rosa S; Andreas Kopp P; Germann S; Maspoli-Conconi M; Sempoux C; Bulliard JL
Cancer Med; 2020 Dec; 9(24):9454-9461. PubMed ID: 33078908
[TBL] [Abstract][Full Text] [Related]
18. Correlation of World Health Organization 2010 Classification for Gastroenteropancreatic Neuroendocrine Neoplasms with the Prognosis of Ovarian Neuroendocrine Neoplasms: Kansai Clinical Oncology Group-Protocol Review Committee/Intergroup Study.
Kai K; Nasu K; Nishida H; Daa T; Shikama A; Shiozaki T; Kurakazu M; Yano M; Imamura Y; Tokunaga H; Tasaki K; Iida Y; Yamada Y; Morisawa H; Nakagawa S; Fujimoto E; Tsuruta T; Matsumoto H; Arakawa A; Nonaka M; Takano H; Ushiwaka T; Mori T; Ito K; Motohashi T; Teramoto N; Yamada T
Neuroendocrinology; 2021; 111(4):320-329. PubMed ID: 32097950
[TBL] [Abstract][Full Text] [Related]
19. Sex-Based Differences in Prognosis of Patients With Gastroenteropancreatic-Neuroendocrine Neoplasms: A Population-Based Study.
Abdel-Rahman O; Fazio N
Pancreas; 2021 May-Jun 01; 50(5):727-731. PubMed ID: 34016894
[TBL] [Abstract][Full Text] [Related]
20. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).
Garcia-Carbonero R; Capdevila J; Crespo-Herrero G; Díaz-Pérez JA; Martínez Del Prado MP; Alonso Orduña V; Sevilla-García I; Villabona-Artero C; Beguiristain-Gómez A; Llanos-Muñoz M; Marazuela M; Alvarez-Escola C; Castellano D; Vilar E; Jiménez-Fonseca P; Teulé A; Sastre-Valera J; Benavent-Viñuelas M; Monleon A; Salazar R
Ann Oncol; 2010 Sep; 21(9):1794-1803. PubMed ID: 20139156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
